Table 1. Antibiotic susceptibility and incidence of ESBL-producing Escherichia coli from 2008 to 2017.
| Susceptibility, % (Total = 1,496) | 2008 (n = 88) | 2009 (n = 90) | 2010 (n = 94) | 2011 (n = 124) | 2012 (n = 164) | 2013 (n = 195) | 2014 (n = 190) | 2015 (n = 146) | 2016 (n = 224) | 2017 (n = 181) | P value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of patients with susceptibility to antibiotics | ||||||||||||
| Ampicillin | 37.5 | 35.6 | 41.5 | 34.7 | 32.9 | 36.1 | 32.8 | 34.2 | 27.2 | 35.4 | 0.508 | |
| PIP-TAZ | 98.9 | 96.7 | 96.8 | NA | 96.2 | 91.8 | 94.7 | 93.8 | 87.9 | 87.3 | < 0.001 | |
| Cefazolin | 89.8 | 76.7 | NA | 64.5 | 70.7 | 79.5 | 74.2 | 65.8 | 62.5 | 62.7 | < 0.001 | |
| Cefotaxime | 95.5 | 91.1 | 87.1 | 85.5 | 81.7 | 81.5 | 78.4 | 69.7 | 67.9 | 68.0 | < 0.001 | |
| Cefepime | 95.5 | 93.3 | 95.7 | 95.2 | 94.5 | 92.8 | 87.8 | 78.8 | 77.7 | 78.5 | < 0.001 | |
| Aztreonam | 97.7 | 92.2 | 92.5 | 94.4 | 89.0 | 87.2 | 79.5 | 79.5 | 78.6 | 76.2 | < 0.001 | |
| Imipenem | 98.9 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | ||
| Ertapenem | NA | NA | NA | NA | NA | 99.5 | 100.0 | 99.3 | 99.5 | 100.0 | ||
| Gentamicin | 79.5 | 75.6 | 74.5 | 77.4 | 75.0 | 75.4 | 69.2 | 69.2 | 63.4 | 65.7 | 0.018 | |
| Amikacin | 100.0 | 98.9 | 97.9 | 97.6 | 98.8 | 100.0 | 99.3 | 99.3 | 99.1 | 98.9 | ||
| TMP-SMX | 68.2 | 63.3 | 72.3 | 69.4 | 68.9 | 70.8 | 62.3 | 62.3 | 62.5 | 65.7 | 0.568 | |
| Ciprofloxacin | 79.5 | 71.1 | 66.0 | 67.7 | 71.3 | 64.6 | 58.9 | 58.9 | 51.8 | 58.6 | < 0.001 | |
| ESBL | 4.5 | 10.0 | 13.8 | 12.9 | 18.9 | 15.9 | 18.9 | 28.1 | 29.9 | 33.1 | < 0.001 | |
ESBL = extended spectrum β-lactamase, E. coli = Escherichia coli, NA = not applicable, PIP-TAZ = piperacillin-tazobactam, TMP-SMX = trimethoprim-sulfamethoxazole.